Edward Clouston MacPherson - 25 Mar 2024 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Reporting relationship: Director
Issuer ticker: MIRA
Reported as of: 25 Mar 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Mar 2024, 17:53:35 UTC
Prior SEC filing: 22 Mar 2024
Next SEC filing: 15 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Edward MacPherson

Key filing fact

Edward Clouston MacPherson filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 27 Mar 2024.

Key facts

This page summarizes Edward Clouston MacPherson's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Mar 2024, 17:53.

Change

Previous filing in this sequence was filed on 22 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRA transaction Derivative

Nonqualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 25 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $1.16
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025.